Business Context and Reporting Period
Company: Genesis Biopharma, Inc. (Note: Request metadata listed "IOVANCE BIOTHERAPEUTICS, INC.", but the filing text identifies the registrant as Genesis Biopharma, Inc., a development-stage biopharmaceutical company formerly known as Freight Management Corp.)
Reporting Period: Quarterly report (Form 10-Q) for the period ended June 30, 2011.
Business Overview: The Company pivoted from an inactive freight management plan to a biopharmaceutical focus in March 2010. It is developing anti-CD55+ antibody programs (GBP-102) for cancer treatment and an autologous cell therapy (Cōntego) for metastatic melanoma. The Company has no revenue-generating operations and relies on equity and debt financing.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2011 | Three Months Ended June 30, 2011 | As of June 30, 2011 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(11,524,036) | $(10,959,741) | N/A |
| Operating Expenses | $11,219,434 | $10,561,185 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $268,565 |
| Total Assets | N/A | N/A | $466,166 |
| Total Liabilities | N/A | N/A | $1,870,111 |
| Stockholders' Equity (Deficiency) | N/A | N/A | $(1,403,945) |
| Derivative Liability | N/A | N/A | $1,739,473 |
| Net Cash Used in Operating Activities | $(1,830,043) | N/A | N/A |
| Net Cash Provided by Financing Activities | $823,000 | N/A | N/A |
Material Changes vs. Prior Period
- Explosion in Operating Expenses: Operating expenses surged to $10.56 million for the three months ended June 30, 2011, compared to $84,629 in the same period in 2010. This increase is attributed to the transition to biopharmaceutical operations, including professional fees, salaries, and significant non-cash stock-based compensation.
- Stock-Based Compensation: A material portion of the 2011 expenses consists of non-cash charges for shares issued for services ($4.2 million and $3.965 million recorded in the six-month period) and fair value adjustments for stock options and warrants.
- Derivative Liability Volatility: The fair value of derivative liabilities (warrants with anti-dilution provisions) increased from $792,575 at December 31, 2010, to $1,739,473 at June 30, 2011. This resulted in a non-cash loss of $304,602 for the six-month period.
- Liquidity Decline: Cash balances decreased from $1,292,469 at December 31, 2010, to $268,565 at June 30, 2011, despite raising $823,000 in net financing proceeds during the period.
Guidance, Outlook, and Risks
- Going Concern: Management explicitly states that the Company's ability to continue as a going concern is dependent on its ability to develop additional sources of capital. The Company has an accumulated deficit of $13.2 million and expects to continue incurring net losses.
- Liquidity Outlook: Management believes current cash resources ($268,565) are sufficient to sustain operations for approximately six months. Additional financing is required in the next quarter to continue product development.
- Recent Financing (Subsequent Event): In July 2011, the Company completed a $5 million offering of 7% senior convertible notes and warrants. The first tranche of $2.5 million was received; the second tranche is held in escrow pending the execution of a license agreement with the U.S. Government regarding tumor infiltrating lymphocytes.
- Strategic Partnership: In August 2011, the Company signed a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) and National Cancer Institute (NCI) to develop adoptive cell immunotherapies for metastatic melanoma.
- Risks: Risks include the inability to secure additional financing, the early-stage nature of product development, and the potential for significant dilution from future equity or convertible debt issuances.
Investor Verification Checklist
- Capital Runway: Verify if the Company has secured the remaining $2.5 million from the July 2011 convertible note offering, which is contingent on signing a specific government license agreement by November 30, 2011.
- Derivative Liability Impact: Assess the impact of the $1.74 million derivative liability on future balance sheets and potential dilution if warrants are exercised or re-priced due to future down-rounds.
- Stock-Based Compensation: Review the magnitude of non-cash expenses related to stock issuances for services and options, which significantly inflated the reported net loss.
- CRADA Progress: Monitor the progress of the CRADA with the NIH/NCI, as this is a key strategic milestone for the Cōntego product candidate.
- Related Party Transactions: Note the $50,000 advance to OXIS International, Inc. (a related party) for potential licensing negotiations and the free office space provided by directors.